In conclusion, MAGE-A4 represents a potential therapeutic target and prognostic marker for TNBC and certain other breast cancer subtypes, holding significant clinical relevance and research value in the field of tumor immunotherapy. This evidence concerns the gene MAGEA4 and breast cancer.